Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy

@article{Kikushima2017ComparisonOT,
  title={Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy},
  author={Wataru Kikushima and Yoichi Sakurada and Atsushi Sugiyama and Seigo Yoneyama and N. Tanabe and Mio Matsubara and F. Mabuchi and H. Iijima},
  journal={Scientific Reports},
  year={2017},
  volume={7}
}
Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the first-line treatment for polypoidal choroidal vasculopathy (PCV), along with anti-VEGF monotherapy. In this study, 100 eyes with treatment-naïve PCV were initially treated with PDT combined with intravitreal ranibizumab (IVR; n = 57) or aflibercept (IVA; n = 43). We compared two-year outcomes between these two groups and investigated factors associated with visual… Expand
...
1
2
...

References

SHOWING 1-10 OF 44 REFERENCES
Two-year results of photodynamic therapy with or without intravitreal ranibizumab for polypoidal choroidal vasculopathy.
  • Yoichi Sakurada, H. Iijima
  • Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2013
Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy
...
1
2
3
4
5
...